Sigma Buys IHC Business
Based in Rocklin, California, Cell Marque has more than 90 employees. The acquisition will complement Sigma’s existing line of IHC antibodies. Cell Marque supplies primary antibodies to Roche’s Ventana Medical Systems business. In September, Cell Marque entered into a 10-year strategic-marketing agreement for Abcam’s IVD IHC RabMab antibodies.
St. Louis, MO 10/3/14—Sigma-Aldrich has agreed to acquire Cell Marque for an undisclosed amount. Cell Marque designs, develops and manufactures antibody reagents and kits for immunohistochemistry. “We expect that Cell Marque’s strong in vitro diagnostic (IVD) antibody product lines and solid relationships with pathologists and companies that provide automated staining instrumentation will broaden the diagnostic-health reach of Sigma-Aldrich,” said Frank Wicks, Ph.D., president of Sigma-Aldrich’s Applied Business Unit. “Cell Marque’s scientific knowledge and experience in the design, validation and manufacturing of IVD antibodies for immunohistochemistry make them an attractive addition to our business, complementing our workflow solutions aimed at IVD customers.” The transaction will close by the end of the year and is expected to be neutral to mildly accretive to EPS in 2015.
